Literature DB >> 1804650

Prokinetic effect of AS-4370 on gastric emptying in healthy adults.

T Kanaizumi1, H Nakano, Y Matsui, H Ishikawa, R Shimizu, S Park, N Kuriya.   

Abstract

The effect of AS-4370 on gastric emptying was investigated in healthy adults using 99mTc-DTPA. Single doses of AS-4370 2.5, 5 or 10 mg or placebo were administered to 12 subjects in a controlled, double-blind, cross-over study. Tests were performed twice weekly in each subject. Thirty min after administration of test drug or placebo, each subject swallowed a bun and orange juice containing 200 microCi nuclide. The radioactivity of the gastric content was measured for 40 min and the activity of the residue was expressed as a percentage of count at the initiation of measurements. The percentage radioactivity, AUC and gastric emptying time fitted by a power exponential curve, were analyzed. No significant difference was observed between the three dose levels of AS-4370 and placebo in half emptying time. However, decreases in the percentage of radioactivity with time were noted; 5 mg at 10 to 16 min and 10 mg at 8 to 24 min after the start of recording. Lower AUCs after 5 mg and 10 mg compared to placebo were also found. The half emptying time was also shorter after 5 mg and 10 mg than placebo. There was no difference in these parameters between 2.5 mg and placebo. The results indicate that AS-4370 5 and 10 mg but not 2.5 mg accelerates gastric emptying in healthy adults.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1804650     DOI: 10.1007/BF00314963

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  4 in total

1.  The analysis of the two-period repeated measurements crossover design with application to clinical trials.

Authors:  S Wallenstein; A C Fisher
Journal:  Biometrics       Date:  1977-03       Impact factor: 2.571

2.  Analysis of gastric emptying data.

Authors:  J D Elashoff; T J Reedy; J H Meyer
Journal:  Gastroenterology       Date:  1982-12       Impact factor: 22.682

3.  AS-4370, a novel gastrokinetic agent free of dopamine D2 receptor antagonist properties.

Authors:  N Yoshida; H Omoya; M Oka; K Furukawa; T Ito; T Karasawa
Journal:  Arch Int Pharmacodyn Ther       Date:  1989 Jul-Aug

4.  Gastric emptying in patients with gastric and duodenal ulcer.

Authors:  T Kanaizumi; H Nakano; T Matsui; H Tatsumi; H Ishikawa; H Kuramoto; R Shimizu; T Shiratori
Journal:  Tohoku J Exp Med       Date:  1989-06       Impact factor: 1.848

  4 in total
  10 in total

Review 1.  Gastroparesis: current diagnostic challenges and management considerations.

Authors:  Shamaila Waseem; Baharak Moshiree; Peter V Draganov
Journal:  World J Gastroenterol       Date:  2009-01-07       Impact factor: 5.742

Review 2.  Efficacy of mosapride plus proton pump inhibitors for treatment of gastroesophageal reflux disease: a systematic review.

Authors:  Qing Liu; Chen-Chen Feng; Er-Man Wang; Xiu-Juan Yan; Sheng-Liang Chen
Journal:  World J Gastroenterol       Date:  2013-12-21       Impact factor: 5.742

3.  Can mosapride citrate reduce the volume of lavage solution for colonoscopy preparation?

Authors:  Masahiro Tajika; Yasumasa Niwa; Vikram Bhatia; Shinya Kondo; Tsutomu Tanaka; Nobumasa Mizuno; Kazuo Hara; Susumu Hijioka; Hiroshi Imaoka; Koji Komori; Kenji Yamao
Journal:  World J Gastroenterol       Date:  2013-02-07       Impact factor: 5.742

4.  The prokinetic effect of mosapride citrate combined with omeprazole therapy improves clinical symptoms and gastric emptying in PPI-resistant NERD patients with delayed gastric emptying.

Authors:  Seiji Futagami; Katsuhiko Iwakiri; Tomotaka Shindo; Tetsuro Kawagoe; Akane Horie; Mayumi Shimpuku; Yuriko Tanaka; Noriyuki Kawami; Katya Gudis; Choitsu Sakamoto
Journal:  J Gastroenterol       Date:  2009-12-10       Impact factor: 7.527

5.  Efficacy of mosapride citrate with polyethylene glycol solution for colonoscopy preparation.

Authors:  Masahiro Tajika; Yasumasa Niwa; Vikram Bhatia; Hiroki Kawai; Shinya Kondo; Akira Sawaki; Nobumasa Mizuno; Kazuo Hara; Susumu Hijioka; Kazuya Matsumoto; Yuji Kobayashi; Akira Saeki; Asana Akabane; Koji Komori; Kenji Yamao
Journal:  World J Gastroenterol       Date:  2012-05-28       Impact factor: 5.742

Review 6.  Mosapride in gastrointestinal disorders.

Authors:  Monique P Curran; Dean M Robinson
Journal:  Drugs       Date:  2008       Impact factor: 9.546

Review 7.  Systematic review: cardiovascular safety profile of 5-HT(4) agonists developed for gastrointestinal disorders.

Authors:  J Tack; M Camilleri; L Chang; W D Chey; J J Galligan; B E Lacy; S Müller-Lissner; E M M Quigley; J Schuurkes; J H De Maeyer; V Stanghellini
Journal:  Aliment Pharmacol Ther       Date:  2012-02-22       Impact factor: 8.171

8.  Early effect on intragastric pH of oral administration of rabeprazole with mosapride compared with rabeprazole alone.

Authors:  Hiroshi Iida; Megumi Kaai; Yumi Inoh; Kenji Kanoshima; Kanji Ohkuma; Takashi Nonaka; Koji Fujita; Tomonori Ida; Akihiko Kusakabe; Shin Maeda; Atsushi Nakajima; Masahiko Inamori
Journal:  Ann Gastroenterol       Date:  2017-05-19

9.  Effects of the Addition of Mosapride to Gastroesophageal Reflux Disease Patients on Proton Pump Inhibitor: A Prospective Randomized, Double-blind Study.

Authors:  Hyun Chul Lim; Jie-Hyun Kim; Young Hoon Youn; Eun Hee Lee; Byung Keon Lee; Hyojin Park
Journal:  J Neurogastroenterol Motil       Date:  2013-10-07       Impact factor: 4.924

Review 10.  DA-9701: A New Multi-Acting Drug for the Treatment of Functional Dyspepsia.

Authors:  Yong Sam Kwon; Miwon Son
Journal:  Biomol Ther (Seoul)       Date:  2013-05-30       Impact factor: 4.634

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.